The IPC Rapid Communications initiative aims to deliver concise, expert perspectives on emerging developments in psoriasis research, clinical practice, and health policy. Each publication highlights urgent or important issues where swift dissemination of expert insights can inform and improve patient care worldwide.
New discoveries, therapies, and data in psoriasis care evolve quickly—and clinicians need access to expert interpretation as soon as possible.
Rapid Communications allow IPC experts to respond to new evidence or pressing issues in real time, bridging the gap between guideline updates and helping practitioners stay current with global best practices.
Each Rapid Communication is a short, focused publication, typically under 500 words with up to five references, developed by IPC experts. Up to four are released annually and may take the form of expert commentaries, white papers, or position statements.
Selected manuscripts are fast-tracked for publication in peer-reviewed journals or shared on the IPC website to ensure timely global access.
Ideas are solicited annually from IPC members, Corporate Partners, and patient partner organizations. Submissions are evaluated by the IPC Editorial Committee based on:
Authors are chosen from among those who proposed the idea with attention to expertise and geographic diversity. While IPC aims to include idea contributors whenever possible, participation as an author is not guaranteed. Each manuscript undergoes a structured review and approval by the IPC Board of Directors before publication.
Stay up to date with the newest expert commentaries shaping psoriasis care.
These key clinical topics are under active development for upcoming Rapid Communication publications.
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
